Abstract: The present invention provides for selection of livestock animals, including bovines, whose genotypes based in the STAT6 gene are correlated with phenotypes reflecting desirable carcass and feedlot traits. These phenotypes include back fat (BFAT), calculated yield grade (CALCYG), cutability (CUT), hot carcass weight (HCW), dry matter intake (DMI), days on feed (DOF), back fat rate (BFAT RATE) and average daily gain (ADG), based on the knowledge of the STAT6 genotypes. The predictive value is based in part on the discovery that certain single nucleotide polymorphisms (SNPs) within the STAT6 gene are linked to phenotypes of economically these important carcass and feedlot traits. Also provided are SNPs within the STAT6 gene useful in reliably distinguishing between a Bos taurus and a Bos indicus bovine.

Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.

Abstract: The present invention provides for selection of livestock animals, including bovines, whose genotypes based in the STAT6 gene are correlated with phenotypes reflecting desirable carcass and feedlot traits. These phenotypes include back fat (BFAT), calculated yield grade (CALCYG), cutability (CUT), hot carcass weight (HCW), dry matter intake (DMI), days on feed (DOF), back fat rate (BFAT RATE) and average daily gain (ADG), based on the knowledge of the STAT6 genotypes. The predictive value is based in part on the discovery that certain single nucleotide polymorphisms (SNPs) within the STAT6 gene are linked to phenotypes of economically these important carcass and feedlot traits. Also provided are SNPs within the STAT6 gene useful in reliably distinguishing between a Bos taurus and a Bos indicus bovine.

Abstract: Disclosed are plasmids that contain and express in vivo in a feline host cell nucleic acid molecules. The plasmid can include nucleic molecule(s) having sequence(s) encoding infectious peritonitis virus M; feline immunodeficiency virus env, or gag, or pro, or gag and pro, or env and gag and pro; rabies G; or feline leukemia virus env and/or gag. Compositions containing such plasmids, methods of use employing such plasmids, and kits involving such plasmids, are also disclosed.

Abstract: Disclosed is an immunological or vaccine composition that includes at least one plasmid that contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen, such as rabies G. The plasmid can include more that one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.

Abstract: This invention provides a DNA vaccine which comprises a naked DNA incorporating and expressing in vivo a nucleotide sequence encoding an antigenic polypeptide, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the polymers of acrylic or methacrylic acid and copolymers of maleic anhydride and alkenyl derivative. The adjuvant compound is preferably a carbomer or an EMA®. This invention also provides a method of enhancing a DNA vaccine and/or the immunogenicity of a DNA vaccine.

Abstract: An in vivo replicative and recombined porcine adenovirus characterized in that it comprises a heterologous nucleotide sequence inserted into the porcine adenovirus in conditions enabling the latter to be replicated in vivo and to express the inserted heterologous nucleotide sequence, and in that the adenovirus genome comes from a 3 or 5 serotype (PAV-3 or PAV-5) adenovirus. Insertion occurs in a non-essential zone of the E3 region, preferably with deletion of said zone. The invention also relates to a recombined porcine vaccine comprising one such porcine adenovirus. The invention further relates to a serotype 3 or 5 porcine adenovirus vector that is replicative in vivo and is deleted in a non-essential region of the genome thereof. The invention also relates to a DNA fragment comprising all or part of the referenced SEQ ID NO.5 nucleotide sequence.

Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.

Abstract: Immunogenic preparations and vaccines, in particular which are inactivated, effective against feline calicivirosis, based on an FCV virus strain 431 as deposited at the CNCM under the accession number CNCM I-2166, or one of its equivalents, in a veterinarily acceptable vehicle or excipient, preferably combined with FCV virus obtained from another FCV strain, in particular strain G1 as deposited at the CNCM under the accession number CNCM I-2167.

Abstract: In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise: (1) a composition comprising (A) an effective amount of a 1-phenylpyrazole derivative; and/or (B) an effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent; (2) an acceptable liquid carrier vehicle; and (3) optionally, a crystallization inhibitor. The invention also provides for a method of treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal or bird an effective amount of a composition according to the present invention.

Abstract: The invention relates to immunogenic preparations or vaccines comprising, on the one hand, a plasmid encoding and expressing a gene from PCV, in particular selected from the group consisting of ORF1 of PCV-2, ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on the other hand, an element capable of increasing the immune response directed against the product of expression of the gene, which can be a carbomer, a porcine cytokine, e.g. GM-CSF or a cationic lipid of formula in which R1 is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R2 is another aliphatic radical comprising from 2 to 3 carbon atoms, andt X is an hydroxyle ou amine group. The cationic lipid can be DMRIE, possibly coupled with DOPE.

Abstract: An immunogenic preparation or vaccine against avian pneumovirosis, comprising an antigen of the avian pneumovirus strain C990427, in a vehicle or excipient which is acceptable from the veterinary point of view and, optionally, an adjuvant.

Abstract: The invention relates to the sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431. It also relates to the sequence of the capsid gene as well as the cDNA sequence of a complementary strain called G1. The cDNA sequences may be incorporated into expression vectors for the preparation of immunogenic preparations and of recombinant or subunit vaccines allowing vaccination against feline calicivirosis.

Abstract: The invention features non-transformant immortal avian cells, in particular derived from avian tissues, i.e., other than blood or hematopoietic cells, particularly fibroblasts and epithelial cells, for instance of embryos. The avian cells are immortalized by the SV40 T+t gene in the dependence of the MTI promoter. In particular they integrate the pDAMT vector.

Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution: a) an insecticidal active substance of formula (I), b) a crystallization inhibitor, c) an organic solvent having a dielectric constant of between 10 and 35, preferably of between 20 and 30, d) an organic co-solvent having a boiling point below 100° C., preferably below 80° C., and a dielectric constant of between 10 and 40, preferably of between 20 and 30.

Abstract: Improved vaccines or immunogenic or immunological compositions, and methods for making and using the same.

Abstract: Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.

Abstract: A spot-on composition for the treatment or protection of a domestic animal against parasitic infestation comprising, (a) an insecticidal active substance of the formula (X): (b) an organic solvent; and (c) a vehicle; and (d) an emollient; wherein the composition comprises from 0.05 to 25% weight/volume of the compound of formula (X), and the compound of formula (X) is applied in a dose between 0.1 and 2 mg/kg animal weight.

Abstract: Method for eradicating fleas in domestic or accommodation premises of a domestic or laboratory mammal is provided. The method involves topically applying, at least monthly, to the domestic or laboratory mammal, a parasitically effective amount of compound of Formula I.

Abstract: The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in particular a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol (carbomer), in particular cross-linked with an allyl sucrose or with allylpentaerythritol. It may also be a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.